Amicus Therapeutics Inc (FOLD)
9.50
-0.09
(-0.94%)
USD |
NASDAQ |
Nov 21, 16:00
9.485
-0.02
(-0.16%)
After-Hours: 20:00
Amicus Therapeutics Net Income (Quarterly): -6.729M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -6.729M |
| June 30, 2024 | -15.70M |
| March 31, 2024 | -48.42M |
| December 31, 2023 | -33.84M |
| September 30, 2023 | -21.58M |
| June 30, 2023 | -43.23M |
| March 31, 2023 | -52.93M |
| December 31, 2022 | -55.86M |
| September 30, 2022 | -33.29M |
| June 30, 2022 | -62.16M |
| March 31, 2022 | -85.26M |
| December 31, 2021 | -83.28M |
| September 30, 2021 | -50.29M |
| June 30, 2021 | -51.22M |
| March 31, 2021 | -65.66M |
| December 31, 2020 | -71.40M |
| September 30, 2020 | -64.01M |
| June 30, 2020 | -52.49M |
| March 31, 2020 | -88.95M |
| December 31, 2019 | -89.73M |
| September 30, 2019 | -61.81M |
| June 30, 2019 | -84.55M |
| March 31, 2019 | -120.30M |
| December 31, 2018 | -78.08M |
| September 30, 2018 | -159.16M |
| Date | Value |
|---|---|
| June 30, 2018 | -61.83M |
| March 31, 2018 | -49.92M |
| December 31, 2017 | -69.21M |
| September 30, 2017 | -111.67M |
| June 30, 2017 | -48.14M |
| March 31, 2017 | -54.99M |
| December 31, 2016 | -58.65M |
| September 30, 2016 | -46.65M |
| June 30, 2016 | -51.05M |
| March 31, 2016 | -43.69M |
| December 31, 2015 | -42.90M |
| September 30, 2015 | -37.80M |
| June 30, 2015 | -27.13M |
| March 31, 2015 | -24.29M |
| December 31, 2014 | -21.22M |
| September 30, 2014 | -17.15M |
| June 30, 2014 | -14.61M |
| March 31, 2014 | -15.94M |
| December 31, 2013 | -12.24M |
| September 30, 2013 | -14.59M |
| June 30, 2013 | -15.35M |
| March 31, 2013 | -17.46M |
| December 31, 2012 | -10.02M |
| September 30, 2012 | -16.29M |
| June 30, 2012 | -9.343M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-89.73M
Minimum
Dec 2019
-6.729M
Maximum
Sep 2024
-53.80M
Average
-52.71M
Median
Net Income (Quarterly) Benchmarks
| Tonix Pharmaceuticals Holding Corp | -14.21M |
| Alnylam Pharmaceuticals Inc | -111.57M |
| Ionis Pharmaceuticals Inc | -140.48M |
| Arbutus Biopharma Corp | -19.72M |
| Krystal Biotech Inc | 27.18M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 141.52M |
| Total Expenses (Quarterly) | 116.72M |
| EPS Diluted (Quarterly) | -0.02 |
| Enterprise Value | 3.005B |
| Gross Profit Margin (Quarterly) | 90.62% |
| Profit Margin (Quarterly) | -4.75% |
| Earnings Yield | -3.58% |
| Operating Earnings Yield | 0.50% |
| Normalized Earnings Yield | -2.947 |